
Apligraf demonstrates significant change in chronic wound's genomic profile
Apligraf - an FDA-approved, bioengineered living-cell therapy from Organogenesis Inc. - has become the first wound-healing therapy to demonstrate a significant change in the genomic profile of a treated non-healing wound, ...
Jan 5, 2017
0
2